Therefore, this study aims to explore the effects of miR-138 targeting SEMA4C in BC cells on epithelial-mesenchymal transition and invasion, to verify the potential of miR-138 as a clinical BC tumor marker, and to provide molecular targeted therapy for breast cancer New reference path. Here, SEMA4C is linked to breast carcinoma.